annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 5F Temozolomide and radiation therapy in elderly patients affected by
glioblastomas: A pooled analyses of three prospectic phase II trials.
(Abstract #2070)
A. Fiorentino, S. Chiesa, P. De Bonis, S. Manfrida, G. R. D’Agostino, A. Mangiola,
A. G. Morganti, V. Frascino, C. Anile, M. Balducci
Brd. 5G High-dose radiation therapy using photons and carbon ion radiotherapy in
patients with atypical and anaplastic meningiomas: Relevance of
neuropathologic classification and therapeutic impact of a boost using of
carbon ion radiotherapy. (Abstract #2071)
S. E. Combs, A. von Deimling, J. Debus, D. Schulz-Ertner, C. Hartmann
Brd. 5H Phase II trial of combined temozolomide and pegylated liposomal
doxorubicin in the treatment of patients with glioblastoma multiforme
following concurrent radiotherapy and chemotherapy. (Abstract #2072)
S. Ananda, A. K. Nowak, L. Cher, A. J. Dowling, C. Brown, R. J. Simes,
M. Rosenthal
Brd. 6A Phase I trial of the addition of oral topotecan to standard 5-day temozolomide
for malignant gliomas. (Abstract #2073)
J. Kirkpatrick, J. J. Vredenburgh, D. A. Reardon, A. Desjardins, K. Peters,
S. Gururangan, J. E. Herndon, J. Marcello, S. Woodring, H. S. Friedman
Brd. 6B Prospective validation of the new graded prognostic assessment scale for
brain metastases: A multicenter study. (Abstract #2074)
S. Villa, D. C. Weber, C. Moretones, A. Manes, P. Puyalto, P. Cuadras, J. Bruna,
E. Verger, F. Graus, C. Balana
Brd. 6C Phase II trial of radiation therapy/temozolomide/bevacizumab followed by
bevacizumab/everolimus in the first-line treatment of glioblastoma
multiforme (GBM). (Abstract #2075)
K. C. Shih, D. R. Spigel, H. A. Burris III, R. H. Brown, G. C. Shepard,
J. D. Hainsworth
Brd. 6D MGMT promoter methylation status and DNA mismatch repair genes in
paired primary and recurrent glioblastoma: A translational study of the
German Glioma Network. (Abstract #2076)
J. Tonn, J. Felsberg, N. Thon, S. Eigenbrod, M. Westphal, G. Schackert,
M. Loeffler, F. Kreth, M. Weller, G. Reifenberger, German Glioma Network
Brd. 6E Preoperative blood parameters as biomarkers for high-grade gliomas.
(Abstract #2077)
M. Rosenthal, K. M. Field, P. Gibbs, T. Wohlers, K. Drummond
Brd. 6F Longitudinal analysis of physiologic MRI parameters in patients with newly
diagnosed glioblastoma multiforme to predict outcome. (Abstract #2078)
Y. LI, J. M. Lupo, M. C. Polley, J. C. Crane, W. Bian, S. Cha, S. M. Chang,
S. J. Nelson
Brd. 6G Characterization of pseudoprogression in patients with glioblastoma: Is
histology the gold standard? (Abstract #2079)
I. Melguizo, J. Bruner, N. Guha-Thakurta, K. R. Hess, V. K. Puduvalli
Brd. 6H Quality of life in patients with pure and mixed anaplastic oligodendroglioma
treated with dose-intense temozolomide: A phase II multicenter study.
(Abstract #2080)
N. Hashemi Sadraei, M. S. Ahluwalia, C. Brewer, D. Schiff, P. G. Fisher,
M. C. Chamberlain, S. Panullo, H. B. Newton, P. Elson, D. Peereboom
Brd. 7A Accuracy of a modeling algorithm to optimize perfusion MRI detection of
glioma recurrence. (Abstract #2081)
L. S. Hu, L. C. Baxter, D. S. Pinnaduwage, T. Jensen, A. C. Dueck,
J. M. Eschbacher, J. E. Heiserman, J. P. Karis, J. Debbins, K. M. Schmainda
Brd. 7B Preclinical evaluation of bafetinib for treatment of glioblastoma multiforme.
(Abstract #2082)
V. Velcheti, B. Peterson, D. Levitt, O. Prakash
200